María J. Redondo

IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes

Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study

The heterogeneity of type 1 diabetes: implications for pathogenesis, prevention, and treatment—2024 Diabetes, Diabetes Care, and Diabetologia Expert Forum

The Heterogeneity of Type 1 Diabetes: Implications for Pathogenesis, Prevention, and Treatment—2024 <i>Diabetes</i>, <i>Diabetes Care</i>, and <i>Diabetologia</i> Expert Forum

The Heterogeneity of Type 1 Diabetes: Implications for Pathogenesis, Prevention, and Treatment—2024 <i>Diabetes</i>, <i>Diabetes Care</i>, and <i>Diabetologia</i> Expert Forum

A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes

Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review

A global initiative to deliver precision health in diabetes

Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes

Heterogeneity and endotypes in type 1 diabetes mellitus

Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review

Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review

The Rare and Atypical Diabetes Network (RADIANT) Study: Design and Early Results

Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies

Milder loss of insulin-containing islets in individuals with type 1 diabetes and type 2 diabetes-associated TCF7L2 genetic variants

Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes

Index60 as an additional diagnostic criterion for type 1 diabetes

Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts

Racial-Ethnic Inequity in Young Adults With Type 1 Diabetes

The clinical consequences of heterogeneity within and between different diabetes types

Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

The Influence of Type 2 Diabetes–Associated Factors on Type 1 Diabetes

Single Islet Autoantibody at Diagnosis of Clinical Type 1 Diabetes is Associated With Older Age and Insulin Resistance

Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes

A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk

The Effect of Age on the Progression and Severity of Type 1 Diabetes: Potential Effects on Disease Mechanisms

Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk

Transcription Factor 7-Like 2 (<i>TCF7L2</i>) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes